<?xml version="1.0" encoding="UTF-8"?>
<ref id="bib41">
 <label>41</label>
 <element-citation publication-type="journal" id="sref41">
  <person-group person-group-type="author">
   <name>
    <surname>Wang</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Tabti</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Elderwish</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Abou-Hamdan</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Djehal</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Yu</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Yurugi</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Rajalingam</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Nebigil</surname>
    <given-names>C.G.</given-names>
   </name>
   <name>
    <surname>DÃ©saubry</surname>
    <given-names>L.</given-names>
   </name>
  </person-group>
  <article-title>Prohibitin ligands: a growing armamentarium to tackle cancers, osteoporosis, inflammatory, cardiac and neurological diseases</article-title>
  <source>Cell. Mol. Life Sci.</source>
  <year>2020</year>
  <pub-id pub-id-type="doi">10.1007/s00018-020-03475-1</pub-id>
  <comment>in press</comment>
 </element-citation>
</ref>
